Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of imipenem/cilastatin-XNW4107 versus imipenem/cilastatin/relebactam for hospital-acquired or ventilator-associated bacterial pneumonia
MOH_2023-05-29_012531Phase 3Not yet recruiting
- Sponsor
- Evopoint Biosciences
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pibozobactam, imipenem, cilastatin and relebactam in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) (2 arms), sponsored by Evopoint Biosciences. Planned start May 2023; status: not yet recruiting.
02
Drugs
pibozobactamimipenemcilastatinrelebactam
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on MOH_2023-05-29_012531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-05-29_012531.